215 related articles for article (PubMed ID: 32296914)
41. Plasma cell-free DNA: a potential biomarker for early prediction of severe dengue.
Phuong NTN; Manh DH; Dumre SP; Mizukami S; Weiss LN; Van Thuong N; Ha TTN; Phuc LH; Van An T; Tieu TM; Kamel MG; Morra ME; Huong VTQ; Huy NT; Hirayama K
Ann Clin Microbiol Antimicrob; 2019 Mar; 18(1):10. PubMed ID: 30871553
[TBL] [Abstract][Full Text] [Related]
42. Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin's lymphoma.
Bedewy AM; Elgammal MM; Bedewy MM; El-Maghraby SM
Ann Hematol; 2013 Oct; 92(10):1359-67. PubMed ID: 23652586
[TBL] [Abstract][Full Text] [Related]
43. Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas.
Lee JJ; Kim DH; Lee NY; Sohn SK; Kim JG; Kim HJ; Do YR; Park YH
Br J Haematol; 2007 May; 137(4):329-36. PubMed ID: 17408400
[TBL] [Abstract][Full Text] [Related]
44. The prognostic significance of elevated levels of serum ferritin before chemotherapy in patients with non-Hodgkin lymphoma.
Yoh KA; Lee HS; Park LC; Lee EM; Shin SH; Park DJ; Ye BJ; Kim YS
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):43-9. PubMed ID: 24200518
[TBL] [Abstract][Full Text] [Related]
45. Plasma cfDNA as a potential treatment monitoring and prognostic index in patients withnon-small cell lung cancer.
Chen N; Li G; Li H; Xiang X; Guo G; Ma Q; Zhang Y
Cell Mol Biol (Noisy-le-grand); 2020 Jul; 66(5):208-213. PubMed ID: 33040838
[TBL] [Abstract][Full Text] [Related]
46. Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network.
Rattotti S; Ferretti VV; Rusconi C; Rossi A; Fogazzi S; Baldini L; Pioltelli P; Balzarotti M; Farina L; Ferreri AJM; Laszlo D; Speziale V; Varettoni M; Sciarra R; Morello L; Tedeschi A; Frigeni M; Defrancesco I; Zerbi C; Flospergher E; Nizzoli ME; Morra E; Arcaini L;
Hematol Oncol; 2019 Apr; 37(2):160-167. PubMed ID: 30726562
[TBL] [Abstract][Full Text] [Related]
47. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B
Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881
[TBL] [Abstract][Full Text] [Related]
48. Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma.
Wedge E; Hansen JW; Garde C; Asmar F; Tholstrup D; Kristensen SS; Munch-Petersen HD; Ralfkiaer E; Brown P; Grønbaek K; Kristensen LS
Am J Hematol; 2017 Jul; 92(7):689-694. PubMed ID: 28378885
[TBL] [Abstract][Full Text] [Related]
49. High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Iijima K
Leuk Res; 2002 Mar; 26(3):241-8. PubMed ID: 11792412
[TBL] [Abstract][Full Text] [Related]
50. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
[TBL] [Abstract][Full Text] [Related]
51. Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?
Chihara D; Oki Y; Fanale MA; Westin JR; Nastoupil LJ; Neelapu S; Fayad L; Fowler NH; Cheah CY
Ann Hematol; 2019 May; 98(5):1169-1176. PubMed ID: 30617643
[TBL] [Abstract][Full Text] [Related]
52. The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas.
Jelicic J; Balint MT; Jovanovic MP; Boricic N; Micev M; Stojsic J; Antic D; Andjelic B; Bila J; Balint B; Pavlovic S; Mihaljevic B
Pathol Oncol Res; 2016 Jul; 22(3):567-77. PubMed ID: 26750138
[TBL] [Abstract][Full Text] [Related]
53. [Clinicopathological features and prognostic analysis of 151 patients with primary extra-nodal non-Hodgkin's lymphoma].
Wang C; Yuan C; He H; Bai O
Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):858-62. PubMed ID: 25620485
[TBL] [Abstract][Full Text] [Related]
54. Primary localized stages I and II non-Hodgkin's lymphoma of the nasopharynx: a retrospective 17-year single institutional experience.
Mohammadianpanah M; Ahmadloo N; Mozaffari MA; Mosleh-Shirazi MA; Omidvari S; Mosalaei A
Ann Hematol; 2009 May; 88(5):441-7. PubMed ID: 18931844
[TBL] [Abstract][Full Text] [Related]
55. A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Sasaki K; Umeda M
Leukemia; 1999 Sep; 13(9):1434-40. PubMed ID: 10482996
[TBL] [Abstract][Full Text] [Related]
56. Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma.
Hara T; Tsurumi H; Takemura M; Goto H; Yamada T; Sawada M; Takahashi T; Moriwaki H
Am J Hematol; 2000 Aug; 64(4):257-61. PubMed ID: 10911377
[TBL] [Abstract][Full Text] [Related]
57. Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients.
Papageorgiou A; Ziogas DC; Mavragani CP; Zintzaras E; Tzioufas AG; Moutsopoulos HM; Voulgarelis M
PLoS One; 2015; 10(2):e0116189. PubMed ID: 25723713
[TBL] [Abstract][Full Text] [Related]
58. [Quantitation of Circulating Cell-free DNA in Patients with Lymphoma and Its Clinical Significance].
Chen YY; Guo SQ; Li YH; Wang DM; Liu X; Zhang YX; Wang SY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1390-1396. PubMed ID: 27784363
[TBL] [Abstract][Full Text] [Related]
59. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission.
Vose JM; Rizzo DJ; Tao-Wu J; Armitage JO; Bashey A; Burns LJ; Christiansen NP; Freytes CO; Gale RP; Gibson J; Giralt SA; Herzig RH; Lemaistre CF; McCarthy PL; Nimer SD; Petersen FB; Schenkein DP; Wiernik PH; Wiley JM; Loberiza FR; Lazarus HM; van Biesen K; Horowitz MM
Biol Blood Marrow Transplant; 2004 Feb; 10(2):116-27. PubMed ID: 14750077
[TBL] [Abstract][Full Text] [Related]
60. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
